Key Benefits:
Decision of the Minister for Foreign Trade and Development Cooperation of 20 April 2015 nr. MinBuza-2015.198527, laying down policy rules and a subsidy ceiling for subsidisation under the 2006 SubsidierScheme Ministry of Foreign Affairs (Fund Product Development Partnerships III)
The Minister for Foreign Trade and Development Cooperation,
Having regard to Article 6 of the Subsidy Decision of the Ministry of Foreign Affairs , 1
Having regard to Article 6.2 of the Ministry of Foreign Affairs 2006 ; 2
Decision:
For grant-to-loan on the basis of Article 6.2 of the Ministry of Foreign Affairs 2006 under the Fund Product Development Partnerships III with a view to promoting the development, of medicines, vaccines, diagnostics to counter poverty-related diseases and to counter or prevent SRGR-related diseases. to prevent the occurrence of the Annex policy rules attached to this Decision.
For the purposes of the grant of subsidy under the Product Development Partnerships III, a subsidy ceiling of EUR 86.3 million shall apply for the period from the entry into force of this Decision until 30 September 2020.
1 Applications for a grant under the Fund Product Development Partnerships III shall be submitted from the moment of entry into force of this Decision until 12 June 2015, 15.00.
2 The application is provided with the modest ones required by the policy rules, named in Article 1 .
The distribution of the subsidy ceiling takes place on the basis of an assessment in accordance with the criteria set out in the Annex is laid down in this Decision, provided that all applications which meet the criteria for the first eligibility of the grant of the grant for the grant of the grant of the aid are to be considered within the framework of a balanced agreement. Spread within the meaning of Article 8 (d) of the Ministry of Foreign Affairs of the Subsidies .
This Decision shall enter into force from the day following the day following the publication of the Official Journal, in which it is placed and shall expire on 1 October 2020, except that it shall continue to apply to grants granted before that date.
This Decision will be Annex is placed in the State Official Gazette and at www.government.nl.
TheMinister
for Foreign Trade and Development Cooperation on behalf of these,the Director-General for International Cooperation,
A. C.C. Rebergen
Despite all the progress over the past decade in R&D and innovation for the benefit of world health, 10 million people still die from infectious diseases such as tuberculosis, HIV/AIDS, malaria and other poverty-related diseases every year. disorders. Often, there is a great lack of effective, accessible and affordable medicines, vaccines, diagnostic tools, and other health products. In addition, women/mothers and children, in particular, continue to be disproportionately high health risks due to unintended pregnancies and unsafe abortion, and medicines and health products are often not adapted properly to specific target groups Young people and children, and the conditions in developing countries. Because of these diseases and disorders, more people die, they cannot follow education or contribute to the productivity of the country, which puts economic and development goals under pressure.
Due to the lack of purchasing power of the target group and financial incentives for private sector investment, too little investment in R&D and innovation for health products and technologies is specifically targeted for poverty and SRGR related Diseases and conditions that make them unavailable or are hardly available or unaffordable and inaccessible to the very poorest. But a small part of the world's health research is focused on conditions that provide a large part of the global disease burden. This has stimulated the development of Product Development Partnerships (PDPs) in the 1990s: public-private partnerships that aim to accelerate the development and accessibility of products that are in their development phase. Few private investments can be counted.
Product Development Partnerships (PDPs) are collaborative partnerships that bring together private and public sector stakeholders to research, develop new products, and access new (health related) technologies. to increase products specifically targeted at diseases and diseases which affect mainly poor populations in developing countries. PDPs reduce the risks to individual donors and industrial parties by bringing funding to each other and applying portfolio management strategies. The combined funding supports broad product pipe lines, which does not require any of the partners to bear the full cost. In addition, strong governance structures and independent review processes should ensure efficient and effective implementation of the programmes.
PDPs are focused on developing demand driven products and applications for populations that are hardest hit by poverty and SRGR-related diseases and disorders. The activities of PDPs may be directed at different parts of the product development process, or on closing holes throughout the innovation cycle. With a portfolio approach for R&D and innovation, the PDPs are seeking to make the most promising products more quickly, cheaper and better accessible to the very poorest.
Important features of PDPs are that they:
• To be a partnership of public and private organisations that bring together knowledge and expertise to work efficiently and effectively with a portfolio of new and/or improved demand-driven products for combat purposes. Poverty and SRGR-related diseases and disorders
• Focus on the development and availability of affordable, effective medicines, vaccines, diagnostic tools, and innovative products for specific to poverty and SRGR-related diseases and disorders to reduce poverty and inequality to combat
• To focus on developing products that are unlikely to be developed through normal commercial channels due to market failures (for example, due to lack of audience purchasing power and financial incentives for private investment) sector)
• Work with diversified product portfolio
• Highly efficient works, based on professional management principles and governance structures with low overhead
• Works on the basis of IPR agreements that make products that are in development so cheap and available as quickly as possible to the populations they need the hardest
• Are funded by more than 1 donor with diverse character properties (government, private sector) 3 , NGOs, funds)
• Substantial in-cash or in-child contributions get from the private sector and research partners
The PDP model has been proven to be successful in encouraging an increase in R&D and innovation in this field. Investment by the government has also been a catalyst for the increase in private sector investment in product development for the benefit of the poorest populations via the PDPs, both in cash and in child. PDPs have contributed to the development of more than 40 products in recent years that can be used by these populations.
The Ministry of Foreign Affairs has gained extensive experience of the financial support of PDPs in the period 2006-2009 and 2011-2014. In total, EUR 150 million has been contributed by the Ministry of Foreign Affairs between 2006 and 2015 to the development of medicines, vaccines and diagnostics to combat HIV/AIDS, tuberculosis and malaria. From the recently implemented Review of the Fund Product Development Partnerships 2011-2014 4 it appears that these funds have been well spent and that the PDPs have made significant progress in terms of their objectives and the objectives of the policy framework.
The need for investment in product development and innovation for the purpose of combating poverty and SRGR-related diseases and disorders remains. Poverty-related diseases and diseases in relation to women's reproductive health still lead to disproportionate illness and death burden in developing countries. Health care deficits undermine such socio-economic development and inclusive growth.
PDPs contribute to the implementation of existing policy agendas of the Minister for Foreign Trade and Development Cooperation, including in the area of Sexual and Reproductive Health and Rights (SRGR) as well as to 'from aid to trade', and The Roadmap neglected diseases of the top sector Life Sciences and Health . The support of PDPs contributes to making products more quickly, better and more effectively on the market. With this new framework Fund Product Development Partnerships III The Ministry of Foreign Affairs wants to capitalize the Dutch added value as a flexible financier. This puts the Netherlands on the added value of R&D and innovation in the field of health, for the benefit of these objectives.
The Minister for Foreign Trade and Development Cooperation has therefore decided for the third time to provide funds for the promotion and support of product development for combating poverty-related diseases. diseases and conditions and diseases related to Sexual and Reproductive Health and Rights, by PDPs. For the period from the entry into force of this Decision until 30 September 2020, a total of a maximum of EUR 86.3 million shall be available in the Product Development Partnerships III Fund for supporting PDPs.
The Ministry of Foreign Affairs wants to use this fund to promote product development to combat poverty-related diseases and diseases in relation to sexual and reproductive health.
Promoting product development means faster, cheaper, simpler, more effective and simpler developing medicines, vaccines, diagnostics, and other tools to prevent poverty and SRGR related diseases and disorders, to be diagnosed and treated.
It should be about the development or improvement of products involving market failures (or a high risk of market failure), lack of audience purchasing power and financial incentives for private sector investment, creating a high risk. There is a demonstrable need for public investment.
The results of these grants are multiply:
Primary:
-More, more effective, safer, simpler and/or cheaper products and treatments in the R&D and innovation pipeline and in the market that are qualified and standardized and accessible to all. This is specifically about the development of:
○ Vaccines
○ Medicines
○ Diagnostics
○ Products for the benefit of sexual and reproductive health 5 .
-Increased investment in R&D and innovation in these areas by other donors (public and private)
-Increased interest in and/or contributions from private sector to product development for poverty related diseases and disorders
-Increased involvement and active participation of developing countries in product development partnerships
-Strengthens image of the Netherlands as a knowledge country in the field of poverty-related diseases and disorders
Secondary:
-Enhanced research capacity and capacity in the field of R&D in the target countries for research and production of medicines, vaccines and diagnostics related to poverty and SRGR-related diseases and disorders
-More investment in, and attention to, policy coherence-to poverty-and SRGR-related diseases and disorders
-Increase access for Dutch companies and knowledge institutions to international public and private financing of product development for SRGR-and/or poverty-related disorders
In addition to the provisions of the General administrative law , the Grant Decision Ministry of Foreign Affairs and the Subsidy Scheme Ministry of Foreign Affairs 2006 In view of the foregoing considerations, the following shall apply in the context of the Fund PDFs.
A. What is a Product Development Partnership (PDP):
Within the framework of these policy rules, a PDP is defined as a public interest grouping 6 and private 7 organisations bringing together knowledge and expertise to work in an efficient and effective way to create a portfolio of new and/or improved demand-driven products for the purpose of combating poverty and SRGR related diseases and disorders. Costs and risks shall be borne jointly by the participating parties. The PDP can be established in a developing country as well as in other countries.
9 B. Cooperative, with or without legal personality:
The grouping (the PDP) may have its own legal personality, but this is not a requirement. If the grouping establishes or has established a legal person for the purpose of cooperating, that legal person shall submit the grant application and act as an applicant and, if the application is to be accepted, also as grant recipient. It should be a non-profit-making legal person. The founding parties should be at least one of the public and private organisations.
Cooperation with no legal personality is also possible. In such a case, the grouping of PDP means a non-profit-making contractual non-profit partnership, consisting of at least two legal persons, a public and a private person. It should, of course, be a matter for legal persons, as defined in point A. above. The grant application shall be submitted by one participant of the grouping, the pener. The pilot shall be a legal person for non-profit-making purposes. If the application is honoured, the pener becomes the grant recipient.
9 C. One applicant/grant recipient per grouping:
Only one applicant (in the case of a partnership without legal personality: the pen-manager) can be a grant recipient of a grouping. This grant recipient shall be fully liable to the Minister for the fulfilment of all the obligations attached to the grant, even if the grant is intended to finance the execution of activities by other participants in the project. partnership than this applicant/pener himself.
The products to be developed are specifically suitable for use in developing countries 8 , where poverty and SRGR-related diseases and disorders are often disproportionate and/or a growing number of victims, particularly among the poorest sections of the population (known as the so-called "disease"). Base of the Pyramid). The grant applicant will have to provide a clear analysis of the added value of the products to be developed in these countries in the proposal.
The Fund shall not be subject to any restrictions as regards the support of specific phases in the product development cycle. The products to be developed must be applicable and the fund is expressly not intended for (purely) scientific research. The grant applicant will have to make clear in the proposal what the added value of the potential public investment (namely the grant from the Dutch Ministry of Foreign Affairs) is in the envisaged phase of the R&D and innovation chain. that, in spite of the (potential) major impact, insufficient funds could not be raised for product development without public contribution.
Funds available for the PDPs III Fund are deployed for the development or improvement of products aimed at treating or preventing SRGR and/or poverty-related diseases and disorders, in those areas where financial Support of the Dutch government has a clear added value. These include products for the benefit of:
1. Promotion of sexual and reproductive health
2. Treatment, prevention and diagnosis of poverty-related diseases
3. Treatment, prevention and diagnosis of potential new and declining epidemics
Each grant application shall cover at least one of the priority themes mentioned above, the activities for which grant applications are requested. An application focused on multiple themes does not have to lead to a higher score.
Grant shall be granted only for the necessary costs of the activities envisaged in the light of the objectives pursued and results provided, to the extent that it cannot reasonably be required that they be made from own resources or otherwise. funded. 9
In any case, the following costs are not eligible:
• costs for applying for subsidy;
• financing costs and interest-rate remuneration;
• Sales tax such as VAT and VAT (this also applies to BTW/VAT members of the grouping);
• costs caused by inflation and exchange rate fluctuations.
In order to qualify for subsidy under the PDPs III, a number of threshold criteria will, first and foremost, be met (see paragraphs VII and VIII below) and sufficient compliance will be required in the case of the Fund. assessment criteria (set out in paragraphs IX, X and XI). The assessment criteria shall cover a test of the quality of the applicant organisation, of the proposal and of the grouping. Particular attention will be given to financial, substantive and administrative aspects.
Evaluation of applications and grant recognition shall be carried out through a tender: grant applications shall all be assessed in accordance with the criteria set out in these policy rules. The applications best meet the criteria are eligible as the first for subsidy, within the window of Article 8, third paragraph, point (d) of the Subsidy Decision Ministry of Foreign Affairs .
If the available resources are not sufficient to fully honour all applications which have been assessed as sufficient, the allocation of resources between them will be based on a ranking of the applications according to the criteria which are laid down in these policy rules. In the final distribution of resources, the extent to which an application will be honoured will be related to the extent to which the criteria are met.
The distribution of resources takes place within the framework of Article 8 (3) (d) of the Subsidy Decision of the Ministry of Foreign Affairs: an effort is being made to balance the available resources in a balanced way. the three policy priorities mentioned in Section V: Priority themes are stagnated.
The quality of the applications is crucial. If the quality of one or more subjects does not sufficiently meet the criteria laid down in these policy rules, grants shall be distributed among the themes and organisations of the applications which are sufficiently well established in the field of application of the rules. measures.
Applications for a grant under the PDPs III may be submitted by a PDP which has its own legal personality or by a person with legal personality on behalf of a PDP which has no legal personality. The following threshold criteria shall apply to the PDP with legal personality or the pener on behalf of the PDP without legal personality ('the applicant '):
1. The applicant is, or represents, a partnership of public 10 and private 11 parties; and the applicant shall establish that the cooperation is sustainable, and costs and risks are borne jointly by the participating parties.
2. The applicant is focused on the development and/or delivery of affordable, effective medicines, vaccines, diagnostic tools for specific poverty-related diseases and/or products for the benefit of SRGR-related diseases to to combat poverty and inequality.
3. The applicant shall have legal personality.
4. The applicant shall be non-profit-making.
5. There is cooperation within or by the PDP with at least one private partner and one public party. This in the case of a PDP which itself has legal personality say that the founding parties are a private and a public partner or that the PDP is cooperating with a private partner and a public partner. In the event that the PDP does not have legal personality, these partners should belong to the grouping.
6. The applicant is demonstrably working on the basis of professional management principles and governance.
7. The applicant or the partnership is funded by more than 1 donor who can come from different sectors, such as government, private sector 12 NGOs, funds.
8. The applicant shall establish that as of 1 January 2015 at least 25% of the applicant's annual income comes from sources other than BZ contributions. In the case of a partnership without legal personality, this criterion shall apply to the cooperating partners together. Funds obtained directly or indirectly from the budget of the Ministry of Foreign Affairs (for example, a grant or contribution from a Dutch Embassy) do not count in determining the amount of own revenue.
9. The applicant shall be in a position to provide adequate financial management. The applicant shall ensure, through experience of experience, a targeted and efficient implementation of programmes in the field of activity.
If an application does not comply with one or more of these threshold criteria, this application shall be rejected and not further pending.
1. The activities for which subsidy is sought shall fit within the geographical and thematic scope and the scope of the phases of the product development cycle as referred to in Section V.
2. An application for a grant under the PDPs III Fund relates to activities with a maturity between 1 October 2015 and 1 October 2020.
(3) The activities for which a grant is sought shall be for a period of up to five years.
(4) A grant application shall be at least € 1 million per year and a maximum of € 4 million per year.
5. For activities for which a grant is requested, a grant has not previously been granted from the budget of the Ministry of Foreign Affairs.
6. On the basis of Article 9 of the Subsidy Decision of the Ministry of Foreign Affairs the grant shall be refused if the grant is requested after the start of the activities. It should be noted, for the record, that activities made prior to the submission of the application for the preparation of the project do not lead to a refusal of the subsidy, but that the costs are not eligible for the grant.
7. If grant is requested for an already current product development line, or for a (part of a) product development line for which grant has previously been provided, the activities for which grant is sought in the framework shall be applied PDP III shall refer to a clearly defined part of the product development line which, by its nature or in time, can be clearly distinguished from the previously already launched or subsidised part of the product development line. Product development line.
If an application does not comply with one or more of these threshold criteria, this application shall be rejected and not further pending.
Applications complying with all threshold criteria shall then be assessed in terms of their content to the extent that they meet the following assessment criteria.
1. The applicant shall underwrite the Dutch policy priorities 13 and, in terms of vision, goals and programming, has a strategic added value for achieving progress on the priority themes listed in this policy framework.
2. The applicant plays an active role in catalyzing and mobilizing further (coherent) investment and policy, attention, interest, and or contributions for R&D and innovation for the fight against poverty and SRGR related diseases and disorders of both public and private parties, including, for example, initiatives from the Netherlands (for example, the Life Sciences and Health Summit), the European Commission, and cooperation between developing countries (for example, the European Developing Countries Clinical Trial Partnership EDCTP). The applicant demonstrates that it is working to reduce the amount of funding needs in the area of poverty and SRGR-related diseases and disorders and improving the market in this field.
3. The applicant is working on knowledge sharing between and (research) capacity building of the partners in developing countries. This criterion looks at the extent to which it contributes to increased engagement and active participation of public and private parties from developing countries in product development partnerships, including the research community.
4. The applicant uses an adequate business project and portfolio management focused on results.
5. The applicant works with diversified product portfolios.
1. The grouping has added value and synergy, a good relationship between partners in the partnership and stakeholders in developing countries, and an adequate role and division of roles in terms of contributions from the different partners and stakeholders in developing countries to achieve the intended outcomes; the project is in line with the current core activities and strategy of the collaborative participants.
2. The partnership provides adequate risk management; the potential risks of collaboration in the partnership have been adequately mapped and in this analysis, attention has been paid to the success and risk factors in each case. or the cooperative strengths/strengths of the project, and proposed measures to be taken.
3. In the framework of the partnership, clear arrangements have been made with the partners on knowledge sharing, resources (people, equipment, etc.) and to achieve results. There have also been clear agreements on the intellectual property of the products which will be produced as part of the work (will), so that the poor population in developing countries will have an accessible price of living in developing countries. -treatments and diagnostics are being pursued.
4. The collaborative venture is a leading player in its field of activity.
1. The activities contribute to the objectives of Product Development Partnership Fund III.
2. The intended results will contribute to greater equality (between men and women, between population groups and/or between countries).
3. The proposal demonstrates a clear internal logic and consistency in terms of goals, results, activities and resources, and gives value for money (the relationship between costs (including procurement), activities, and (additional) returns).
4. The intended results are specific, measurable, acceptable, realistic and time-bound (SMART) defined.
5. There is a need for the product to be developed; this is demonstrated in a clear and credible problem analysis, as well as the potential impact on the health status of the BoP, also in the context of other similar initiatives.
6. The public, Dutch investment (i.e. the requested subsidy from the Minister) has added value in the envisaged phase in the R&D and innovation chain and the proposal adequately demonstrates that there is funding-need or funding gap. That is, the (targeted) products are aimed at people in countries where the Disease burden significant, where there is an R&D and innovation emergency and where there is a (public) funding necessity.
7. The proposal provides an adequate understanding of possible barriers to the application of the new vaccine, medicine, diagnostic agent and/or other technique in practice and how it will be dealt with.
8. There is an adequate risk management system: the proposal will provide an adequate basis for the possible risk of the activities being taken. This shall consist of an adequate risk analysis, including corruption, and an adequate system for monitoring and mitigation, including relevant cross-links between parallel activities, and guidance.
9. The proposal describes clear and credible how international quality standards 14 shall be secured in respect of the activities, in particular in the field of clinical studies, ethical aspects and publication obligations.
10. There is an adequate system of monitoring, evaluation and feedback control, including periodic scientific review.
As an indication of the volume of applications, a proposal should preferably include up to 15 pages, excluding annexes.
The application shall be drawn up in the English language and shall be submitted using a table of contents established for that purpose. The application shall be provided for in the Annexes mentioned in paragraph XIV below.
You must follow the order below with any sub-paragraphs and associated page numbers.
| I. |
General Requestor Information |
| II. |
Threshold criteria in relation to the PDP and the applicant |
| III. |
Threshold criteria in relation to the application |
| IV. |
Assessment criteria relating to the quality of the applicant organisation |
| V. |
Assessment criteria relating to the quality of the grouping |
| VI. |
Assessment criteria relating to the quality of the grant application |
| VII. |
Conclusion: signature |
| VIII. |
Mandatory annexes (see Section). XIV of the Policy Framework Fund Product Development Partnerships III) |
| IX. |
Other Annexes |
For the budget, use should be made of the project budget calculation tool, to download via http://english.rvo.nl/pdp.
Applications shall be signed in full and without reservation, and shall be legally signed by the person authorised to do so on behalf of the applicant organisation, stating the name and function of the applicant. The application will preferably be submitted digitally (by email, max. 10 MB), for grant application PDP III, at the latest on Friday 12 June, 3 p.m. Dutch time at the Rijksdienst for Ondernement Nederland; PDP@rvo.nl
Written applications may be sent to:
Rijksdienst van Ondernemend Nederland: PostAddress: Postbus 93144, 2509 AC The Hague, Netherlands, quoting PDP III; Visits: Princess Beatrixlaan 2, The Hague.
Requests submitted later than the said date and time shall not be considered. The applicant organisation shall be the sole responsible for a timely and complete submission of an application.
It is not possible to submit a provisional application.
The participants explain the OECD Guidelines for Multinational Enterprises on Corporate Social Responsibility, the UN Convention on Biological Diversity and the Objectives of the International Labour Organisation. and that they act accordingly; to be aware of the FMO exclusion list and not to carry out any activities under the project named on this list.
Emphasis is placed on application procedure in the application procedure. Article 7, third paragraph, of the Subsidy Decision Ministry of Foreign Affairs . Should an application be submitted incomplete, the Minister may ask for a supplement. The date of receipt of the application shall then be the date on which the application was completed. If an application is only submitted in the last two weeks before the expiry of the deadline, the manager will run the risk that the Minister will not apply his authority to ask for a supplement as the manager is not in charge. such an addition is no longer possible without exceeding the deadline. In such a case, the application will no longer be possible to supplement it, but will be assessed as it was primarily submitted.
The Minister will decide on the applications lodged by 30 September 2015.
The period for granting the grant shall not go earlier than 1 October 2015. Support is given in the form of an activity grant on the basis of: Article 6.2 of the Ministry of Foreign Affairs ' Subsidation . The proposals cover a period of up to 5 years, with the Dutch contribution being earmarked as little as possible. However, the subsidy should not, of course, be used for activities other than those set out in the application and other than those for which the grant was granted. The Minister of Foreign Affairs strives to align accountability requirements in the grant decision with the demands of other donors. This will help the Netherlands to make further harmonisation of donor aid.
Information on the provision of grants under the PDPs III Fund can be contacted by the Rijksdienst van Ondernemend Nederland via PDP@rvo.nl.
The Minister has entrusted the implementation of these policy rules to the State Department for the Netherlands (hereafter RVO.nl), agency of the Ministry of Economic Affairs. RVO.nl will implement these policy rules on behalf of the Minister on the basis of a mandate granted to RVO.nl.
1. Act of constitution and statutes of the applicant organisation.
2. Annual reports and annual accounts covering the years 2012 to 2014 of the applicant organisation. In this respect, the applicant shall establish that as of 1 January 2015 at least 25% of the annual revenue comes from sources other than BZ contributions. The applicant shall build on the plausibility of this on the basis of the revenues for the period 2012-2014.
3. Last statement and management 'letter' of the requesting organisation.
4. Organisational Schedule of the PDP.
5. List of all partners, whether or not there is a contract with each partner, and the division of roles between the partners in the partnership.
(6) In the case of an application for a grouping without legal personality, an agreement which guarantees compliance with the obligations of the Minister to the Minister and which arrangements have been made on the manner Each of the parties participating in the grouping shall contribute to the activities of the grouping, the sharing of costs and risks on the parties, the way in which decisions are taken in the grouping. shall take place and the way in which the supervision of the grouping is organised.
7. Activity plan showing the objectives and results the PDP intends to achieve, and in what way, with the activities to be carried out by him for the next 12 months of the period in which the activities are carried out. Operations at operational level need not be worked out.
8. A detailed and closing budget associated with the activity plan, according to the prescribed format.
9. Liquidity forecast per calendar year for the entire activity period and a statement of financial contributions from other donors.
10. Multi-year plan (summary of activities, objectives, results and expected effects), for the period covered by the application, except the period of time for which the activity plan is already foreseen.
11. Financial multi-annual budget, the period covered by the application, excluding the period covered by the budget as part of the plan of activities. The financial estimate must be broken down by type of expenditure.
In case grant is granted under these policy rules, the following applies:
The pilot shall cooperate in communication to and on the results of the activities, when they are public.
The pilot shall cooperate in an evaluation study or monitoring aimed at the application and effects of the policy rule.
Questions on this paper or other matters can be discussed at the information meeting organised by RVO.nl on 22 May 2015. You can specify for this meeting via PDP@rvo.nl. The exact time and place will be announced at http://english.rvo.nl/pdp.
The report of this meeting will be published on the Internet through this site. Additional questions can be submitted by email at PDP@rvo.nl until 10 June 2015, after which the questions will be answered anonymously by means of publication via the aforementioned Internet site.
